At the 9th Annual Innate Killer Summit (IKS2024), Clinical Activity of GAIA-102 Against Refractory/Relapsed Pediatric Solid Tumors will be presented.

Fukuoka, JAPAN – Yoshikazu YONEMITSU, CSO/STO of GAIA BioMedicine, MD PhD, will present Clinical Activity of GAIA-102 Against Refractory/Relapsed Pediatric Solid Tumors at the 9th Annual Innate Killer Summit (IKS2024)

Summary of the presentation

• • GAIA-102 is an off-the-shelf and ready-for-use formulation, and produced by allogeneic PBMCs from multiple donors with predefined HLA-C and KIR alleles
  • GAIA-102 demonstrates direct and rapid tumor cell killing activity, delayed antitumor response via inducing tumor specific acquired immunity in vivo animal models
  • Some patients in the GAIA-102 single-agent cohort exhibited ‘pseudoprogression’ and ’subsequent shrinkage’ of multiple tumor foci on CT images, suggesting that GAIA-102 can activate tumor-specific CTL in clinical settings

Presentation at the Annual Meeting:

Program: Clinical Translation

Session: Precision Dosing Strategies for Patient Safety & Optimal Therapeutic Efficacy

Scheduled for: March 20, 2024 (Wednesday) 11:45~12:15 (PDT), San Diego Marriott Del Mar

About GAIA BioMedicine:

GAIA BioMedicine, Inc., founded in 2015 by Prof. Yoshikazu YONEMITSU, MD PhD, as a spin-off venture of Kyushu University, is a clinical stage and technology-driven biopharmaceutical company specializing in cell therapies for cancer using NK cells.

Share on